-$0.17 EPS Expected for Renalytix Plc (NASDAQ:RNLX) This Quarter

Equities research analysts expect that Renalytix Plc (NASDAQ:RNLX – Get Rating) will report earnings per share of ($0.17) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Renalytix’s earnings, with estimates ranging from ($0.18) to ($0.17). Renalytix posted earnings per share of ($0.12) during the same quarter last year, which indicates a negative year-over-year growth rate of 41.7%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Renalytix will report full-year earnings of ($0.68) per share for the current fiscal year, with EPS estimates ranging from ($0.71) to ($0.64). For the next financial year, analysts anticipate that the firm will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.66) to ($0.38). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Renalytix.

Renalytix (NASDAQ:RNLX – Get Rating) last issued its earnings results on Thursday, March 31st. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Renalytix had a negative return on equity of 62.67% and a negative net margin of 1,667.00%. The company had revenue of $0.85 million during the quarter.

A number of equities research analysts recently weighed in on the company. BTIG Research dropped their price target on Renalytix from $24.00 to $15.00 and set a “buy” rating for the company in a report on Friday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Renalytix in a report on Friday, April 1st. Zacks Investment Research cut Renalytix from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. Finally, JPMorgan Chase & Co. dropped their price target on Renalytix from $25.00 to $8.00 in a report on Friday, April 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, Renalytix currently has an average rating of “Buy” and an average target price of $23.80.

A number of institutional investors and hedge funds have recently made changes to their positions in RNLX. North Star Investment Management Corp. bought a new position in Renalytix in the 1st quarter valued at $35,000. Advisor Group Holdings Inc. boosted its position in shares of Renalytix by 53.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 11,998 shares of the company’s stock worth $83,000 after purchasing an additional 4,170 shares during the last quarter. Private Advisor Group LLC bought a new position in shares of Renalytix in the 1st quarter worth $92,000. Skye Global Management LP bought a new position in shares of Renalytix in the 4th quarter worth $105,000. Finally, Envestnet Asset Management Inc. boosted its position in shares of Renalytix by 22.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 17,235 shares of the company’s stock worth $119,000 after purchasing an additional 3,126 shares during the last quarter. Hedge funds and other institutional investors own 16.13% of the company’s stock.

Shares of RNLX opened at $3.52 on Tuesday. The stock has a 50 day simple moving average of $5.61 and a 200-day simple moving average of $11.21. Renalytix has a 1 year low of $3.52 and a 1 year high of $35.71. The stock has a market cap of $131.58 million, a PE ratio of -6.40 and a beta of 1.78.

Renalytix Company Profile (Get Rating)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score.

Read More